Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesCertolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/10/09
Duggan ST et al. – Certolizumab pegol is a PEGylated humanized Fab? monoclonal antibody that targets and neutralizes both membrane–bound and soluble tumor necrosis factor (TNF)–alpha, preventing inflammation and consequently the destruction of cartilage and bone. Certolizumab pegol has a relatively long elimination half–life of ?2 weeks, allowing subcutaneous administration once every 2 or 4 weeks...In patients with active rheumatoid arthritis who had previously failed to respond to treatment with >=1 disease–modifying anti–rheumatic drug, certolizumab pegol 400 mg every 4 weeks as monotherapy effectively improved ACR responses at all measured timepoints up to 24 weeks, according to data from the randomized, phase III FAST4WARD trial. Certolizumab pegol was generally well tolerated in combination with methotrexate or as monotherapy in phase III trials in patients with rheumatoid arthritis, with most adverse events being of mild to moderate intensity. Infections were the most frequently reported adverse events.
Related Articles
Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis
Arthritis Care and Research, 11/02/09
Relevance Score: 88%
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: Results from the RAPID 1 randomized controlled trial
Arthritis Research & Therapy, 11/16/09
Relevance Score: 87%
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Orthopedics...keeping you current
Receive free subspecialty "5-minute updates" via email
Meeting the ranging of informational needs of chronic low back pain sufferers: Conceptual design and rationale of the interactive website ONESELF
Disability & Rehabilitation, 12/18/09
The Rare Case of an Intramedullary Cervical Spinal Cord Teratoma in an Elderly Adult: Case Report and Literature Review
Spine, 12/18/09
Cervical Spine Motion Generated With Manual Versus Jackson Table Turning Methods in a Cadaveric C1-C2 Global Instability Model
Spine, 12/18/09
Today in Rheumatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Low cortisol levels in active juvenile idiopathic arthritis
Clinical Rheumatology, 12/20/09
Increased level of tumor necrosis factor-alpha in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state
Rheumatology International, 12/20/09
Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis
Rheumatology, 12/20/09
Sponsor
Article Search
Sponsor
Sponsor